MedTrace Logo

The Role of Renal Resistive Index (RI) in Predicting Acute Kidney Injury Progression in Intensive Care Clinic

NCT06995222 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-05-29

No results posted yet for this study

Summary

Acute kidney injury(AKI) is defined in the KDIGO guidelines as a ≥0.3 mg/dL (≥26.5 micromol/L) increase in serum creatinine in the previous 48 hours or a ≥1.5-fold increase in serum creatinine from baseline, known or presumed to have occurred in the previous seven days, or a urine volume \<0.5 mL/kg/hour for six hours.

Given the high morbidity and mortality associated with AKI, many investigators are studying several novel biomarkers to detect AKI progression earlier, identify etiologies and predict outcomes. However, the utilisation of these novel biomarkers may be constrained by reimbursement considerations.

The renal resistive index (RRI) is a well-established metric for evaluating renal perfusion; however, its application in the context of AKI has been a subject of recent debate. While RRI has been utilised to demonstrate perfusion in acute and chronic renal diseases, particularly in conjunction with ultrasonography, its efficacy remains a subject of scientific discourse. In addition, Boddi reported that RRI is a strong indicator of mortality and a diagnostic marker, especially in patients with persistent AKI.

The present study aims to evaluate the appropriateness of using the RRI, a non-invasive procedure, to determine the progression of AKI stages and the need for renal replacement therapy in patients hospitalised in intensive care units.

Conditions

  • Akut Kidney Injury
  • Renal Replacement Therapy for Acute Kidney Injury in ICU

Interventions

DIAGNOSTIC_TEST

renal resistive index with Doppler ultrasound

Renal resistive index uses doppler ultrasonography which assesses blood flow velocity in the renal arteries. The Renal Resistive Index (RI) is calculated by substracting diastolic velocity from systolic velocity then dividing result by systolic velocity Where: Systolic velocity is the peak velocity of the blood flow during the systolic phase of the cardiac cycle. Diastolic velocity is the velocity of blood flow during the diastolic phase.

Sponsors & Collaborators

  • Gulhane Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Gürhan T associate professor doctor · Gulhane Education and Research Hospital Ankara Türkiye

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-07-01
Completion
2026-07-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06995222 on ClinicalTrials.gov